Showing 916 results
-
Media Release /Pelabresib 144-week Phase III MANIFEST-2 data show sustained clinical effects in longest follow-up from a combination trial in first-line JAKi-naïve myelofibrosis KISQALI® six-year NATALEE…
-
Event / Oct 18, 2026
-
Media Release /Patients continuing ianalumab saw further improvement in systemic disease activity through Week 108, with no new safety findings1 Nearly two-thirds of patients on continuous ianalumab reached low…
-
Media Release /Cosentyx® (secukinumab) doubled sustained remission rates and demonstrated steroid-sparing effects vs placebo in Phase III trial1 Approval marks 11th US indication for Cosentyx,…
-
Media Release /RemIND data show clinically meaningful responses through Week 52 across three most prevalent CIndU subtypes, including after switching from placebo at Week 241 Twice as many Rhapsido-treated…
-
Media Release /Remibrutinib achieved significant and clinically meaningful reduction in relapses vs. teriflunomide, to approximately 1 relapse every 13 years, without the need for chronic B-cell depletion1,2 MRI…
-
Media Release /Six-year NATALEE analysis showed ~20% reduction in risk of death compared to ET alone1 Benefit increased over time in invasive disease-free survival and across key secondary endpoints1-3…
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 92
- › Next page